| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 7 securities · may seek to influence control | ||||||
|
DSS, Inc.
13D/A
DSS · 26253C201
|
86.3% |
9/8/2026
Event 9/3/2026
|
||||
| Heng Fai Ambrose Chan | 86.3% | |||||
| Alset Inc. | 80.0% | |||||
| Global Biomedical Pte. Ltd. | 3.1% | |||||
| Alset International Limited | 71.0% | |||||
|
HWH International Inc.
13D/A
ESYN · 44852G309
|
27.1% |
8/11/2026
Event 8/7/2026
|
||||
| Heng Fai Ambrose Chan | 27.1% | |||||
| Alset Inc. | 18.7% | |||||
| Alset International Limited | 7.4% | |||||
| Alset Acquisition Sponsor, LLC | 2.0% | |||||
|
SHARING SERVICES GLOBAL Corp
13D/A
SHRG · 819536103
|
99.9% |
3/24/2026
Event 2/4/2026
|
||||
| Heng Fai Ambrose Chan | 99.9% | |||||
| Heng Fai Holdings Limited | 0% | |||||
| Alset Inc. | 99.8% | |||||
| HWH International Inc. | 99.8% | |||||
| Alset International Limited | 12.7% | |||||
| Global Biomedical Pte. Ltd. | 2.8% | |||||
|
Alset Inc.
13D/A
AEI · 02115D208
|
90.0% |
9/16/2025
Event 9/12/2025
|
||||
| Heng Fai Ambrose Chan | 90.0% | |||||
| HFE Holdings Limited | 9.9% | |||||
|
Value Exchange International, Inc.
13D/A
SNPY · 829348200
|
69.9% |
4/17/2025
Event 3/28/2025
|
||||
| Heng Fai Ambrose Chan | 69.9% | |||||
| Alset Inc. | 69.7% | |||||
| Hapi Metaverse Inc. | 68.9% | |||||
|
Impact Biomedical Inc.
13D/A
04529L106
|
2.9% |
4/4/2025
Event 4/2/2025
|
||||
| Heng Fai Ambrose Chan | 2.9% | |||||
| Alset Inc. | 2.9% | |||||
| Alset International Limited | 2.9% | |||||
| Global Biomedical Pte. Ltd. | 0% | |||||
|
HWH International Inc. (HWH)
13D/A
HWH · 44852G101
|
90.2% |
12/27/2024
Event 12/24/2024
|
||||
| Heng Fai Ambrose Chan | 90.2% | |||||
| Alset Inc. | 90.1% | |||||
| Alset International Limited | 35.6% | |||||
| Alset Acquisition Sponsor, LLC | 9.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.